spacer
home > advertise
ADVERTISING OPPORTUNITIES
Why Advertise with Samedan?

 

Samedan's range of specialist titles spans the full spectrum of pharmaceutical development, from innovation to patient, and is designed to meet the broad
needs of an industry built on high-quality information, communication, and expertise.

With a history going back more than a decade, Samedan's clients range from long-established industry leaders to the most recent start-ups and university spin-outs.
Many clients have advertised across our entire range for years and have come to
appreciate a strong and cooperative relationship with us.

Samedan is committed to providing the perfect editorial platform for your advert.
That is why our featured articles take an opinion-led, non-promotional view of the industry. This ensures that every advert enjoys maximum impact with each title's readership of 10,000+ key decision makers.

For further information about each of our titles, follow the links below. Each of our advertising executives can be contacted at the email addresses below and will be
pleased to discuss how Samedan can meet your needs.

Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747

European Pharmaceutical Contractor
Louise White: louise@samedanltd.com

European BioPharmaceutical Review
David Hirsh: david@samedanltd.com

International Clinical Trials
Louise White: louise@samedanltd.com

Pharmaceutical Manufacturing and Packing Sourcer
Simon Caplan: simon@samedanltd.com

Innovations in Pharmaceutical Technology
David Hirsh: david@samedanltd.com



spacer

Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

News and Press Releases

Nemeras preservative-free multidose eye dropper Novelia® approved for Santens Cosopt® for Glaucoma treatments in 29 European countries

Nemera is pleased to announce that its multidose eye dropper Novelia® has been approved for the preservative-free formulation Cosopt iMulti® (20mg/ml dorzolamide + 5mg/ml timolol eye drops, solution).
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement